Searching for a cure, Improving lives

Sarepta recruits for Phase 3 ESSENCE trial to test two potential therapies

Posted on: June 19th, 2017 | 0 comments

Sarepta Therapeutics is recruiting up to 99 boys with Duchenne muscular dystrophy to test two new compounds, SRP-4045 and SRP-4053, in a Phase 3 clinical trial.

The ESSENCE study is a double-blind, placebo-controlled, multi-center Phase 3 clinical trial (NCT02500381) with an open-label extension period, evaluating the two drugs’ safety and efficacy in boys between 7 to 13 years of age, with a confirmed deletion amenable to exon 45 or 53 skipping.

Sarepta plans to target at least 45 boys potentially responsive or amenable to exon 45 skipping with SRP-4045, and 45 boys potentially responsive or amenable to exon 53 skipping with SRP-4053. The boys will be randomised to receive once-a-week intravenous infusions of 30 mg/kg SRP-4045 or 30 mg/kg SRP-4053 or placebo, for up to 96 weeks. Then, in the open-label extension phase, all boys will receive open-label active treatment for up to 96 weeks.

After about 75 of the boys have been in the trial for 48 weeks, researchers will review the initial results to determine which patients are eligible to enroll in the open-label extension period.

The study’s primary objective is to test the efficacy of both compounds, which will be assessed at regular study visits, with functional tests such as the six-minute walk test (6MWT). All patients will undergo a muscle biopsy at baseline and a second muscle biopsy at week 48. Sarepta will assess the drugs’ safety through adverse events, laboratory tests, electrocardiograms, echocardiograms, vital signs, and physical examinations. In addition, to assess how both drugs work in the body, researchers will collect blood samples from patients throughout the study.

SRP-4045 and SRP-4053 are designed to address the underlying cause of Duchenne by enabling the production of a shorter, but functional, form of the dystrophin protein. Neither the U.S. Food and Drug Administration nor any other regulatory agency has approved these drugs to treat Duchenne.

Sarepta, based in Cambridge, Massachusetts, is conducting the trial at 17 study sites across the United States, as well as sites in Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden and the United Kingdom. More information about how to enrol in this study can be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Summit presents data from Phase 1 clinical programme of lead utrophin modulator, ezutromid

June 22nd, 2017

Summit Therapeutics has today announced the presentation of clinical data from two Phase 1 clinical trials

Tell me more

What Raxone being given approval through the EAMS scheme means for the Duchenne community

June 22nd, 2017

  Over a number of years we have worked closely with Santhera Pharmaceuticals and other

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne